Evidence map›Paper›PMID 42461083›Full record

ArticleCancer research2026

Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release.

Suisui Hao, Yoshiaki Sato, Zhaojin Liu, Darleny Lizardo, Xinyan Lu, Heinz-Josef Lenz, Robert E Schoen, Jian Yu, Lin Zhang

Abstract read
In one paragraph

Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Suisui HaoNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California (USC), Los Angeles, California.ORCID 0000-0002-5015-3406
Yoshiaki SatoNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California (USC), Los Angeles, California.ORCID 0000-0003-3375-5189
Zhaojin LiuNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California (USC), Los Angeles, California.ORCID 0000-0002-9574-5974
Darleny LizardoUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0002-8509-5250
Xinyan LuNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California (USC), Los Angeles, California.ORCID 0000-0001-9305-4515
Heinz-Josef LenzNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California (USC), Los Angeles, California.ORCID 0000-0003-2178-9568
Robert E SchoenUPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.ORCID 0000-0001-7153-2766
Jian YuNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California (USC), Los Angeles, California.ORCID 0000-0002-4021-1000
Lin ZhangNorris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California (USC), Los Angeles, California.ORCID 0000-0003-0018-3903

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
STING-dependent Intestinal Regeneration upon Radiation InjuryR01CA260900 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YU, JIAN · 2022 to 2025
$2.5M
Targeting defective necroptosis in colorectal cancerR01CA247231 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHANG, LIN · 2020 to 2024
$2.3M
Role of necroptosis in colorectal cancer therapyR01CA236271 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHANG, LIN · 2019 to 2023
$2.2M
BET degraders for improving colorectal cancer therapyR01CA248112 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHANG, LIN · 2021 to 2025
$2.1M
Therapeutic mechanisms of targeting WRN in MSI colorectal cancer.R01CA312130 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Lin Zhang · 2026 to 2026
$582k
Role of p73-mediated DR5 induction in therapeutic response to CDK inhibition.R01CA311678 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Lin Zhang · 2026 to 2026
$561k
National Cancer Institute (NCI) P30CA014089National Cancer Institute (NCI) P30CA047904National Cancer Institute (NCI) R01CA236271National Cancer Institute (NCI) R01CA247231National Cancer Institute (NCI) R01CA248112National Cancer Institute (NCI) R01CA260900National Cancer Institute (NCI) R01CA311678National Cancer Institute (NCI) R01CA312130NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA236271NCI NIH HHS R01 CA247231NCI NIH HHS R01 CA248112NCI NIH HHS R01 CA260900NCI NIH HHS R01 CA311678NCI NIH HHS R01 CA312130
6 · The paper itself

Abstract

Colorectal cancer with microsatellite instability (MSI) is often treated with immune checkpoint inhibitors (ICI), such as anti-PD-1 antibodies. However, a substantial fraction of MSI colorectal cancers do not respond to ICIs. Recent studies have identified the DNA helicase Werner (WRN) as a synthetic lethal target in MSI cancer cells, leading to the development of several small-molecule WRN inhibitors that are currently in clinical trials. In this study, we found that targeting WRN in MSI colorectal cancer cells triggered a robust antitumor immune response. Cell death induced by WRN inhibition was selective in MSI colorectal cancer cells and led to the release of extrachromosomal circular DNA (eccDNA), which directly stimulated immune cell activation and cytokine production. The deletion of nuclear ligase LIG3, a key mediator of eccDNA biogenesis, abolished the antitumor and immunogenic effects of WRN inhibition in MSI colorectal cancer cells and tumors. Furthermore, WRN inhibition potentiated anti-PD-1 therapy in MSI colorectal cancer models, including syngeneic mouse tumors and patient-derived tumor organoids. Together, these results reveal the eccDNA-mediated immunogenic effects of WRN inhibition in MSI colorectal cancer, further strengthening the rationale for combining WRN inhibitors with ICIs. SIGNIFICANCE: Extrachromosomal circular DNA release induced by WRN inhibition in colorectal cancer cells with microsatellite instability stimulates immune cell activation and cytokine production, which can be leveraged to enhance the efficacy of immunotherapy.

Indexed as

Colorectal NeoplasmsDNA, CircularMicrosatellite InstabilityWerner Syndrome HelicaseAnimalsCell Line, TumorExtrachromosomal DNAHumansMiceDNA, CircularExtrachromosomal DNAWerner Syndrome HelicaseWRN protein, human

Identifiers

PMID42461083
PMCPMC13464570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.